Literature DB >> 25128147

Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.

Julie Charles1, Jean-Claude Beani2, Giacomo Fiandrino3, Benoit Busser4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25128147     DOI： 10.1016/j.jaad.2014.03.038

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  12 in total

Review 1.  Histiocytic neoplasms in the era of personalized genomic medicine.

Authors:  Benjamin H Durham; Eli L Diamond; Omar Abdel-Wahab
Journal:  Curr Opin Hematol       Date:  2016-07       Impact factor: 3.284

Review 2.  Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.

Authors:  Matthias Papo; Fleur Cohen-Aubart; Ludovic Trefond; Adeline Bauvois; Zahir Amoura; Jean-François Emile; Julien Haroche
Journal:  Curr Oncol Rep       Date:  2019-05-21       Impact factor: 5.075

3.  Efficacy of BRAF-Inhibitor Therapy in BRAFV600E -Mutated Adult Langerhans Cell Histiocytosis.

Authors:  Antonious Z Hazim; Gordon J Ruan; Aishwarya Ravindran; Jithma P Abeykoon; Caleb Scheckel; Robert Vassallo; Jay H Ryu; W Oliver Tobin; Matthew J Koster; N Nora Bennani; Karen L Rech; Jason R Young; Mithun V Shah; Gaurav Goyal; Ronald S Go
Journal:  Oncologist       Date:  2020-10-12

4.  Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study.

Authors:  Jean Donadieu; Frederic Bernard; Max van Noesel; Mohamed Barkaoui; Odile Bardet; Rosella Mura; Maurizio Arico; Christophe Piguet; Virginie Gandemer; Corinne Armari Alla; Niels Clausen; Eric Jeziorski; Anne Lambilliote; Sheila Weitzman; Jan Inge Henter; Cor Van Den Bos
Journal:  Blood       Date:  2015-07-20       Impact factor: 22.113

5.  BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.

Authors:  Svetlana A Protsenko; Anna I Semionova; Yuri I Komarov; Svetlana N Aleksakhina; Alexandr O Ivantsov; Aglaya G Iyevleva; Evgeny N Imyanitov
Journal:  Invest New Drugs       Date:  2015-08-20       Impact factor: 3.850

6.  Cutaneous Langerhans cell histiocytosis : The spectrum of a rare cutaneous neoplasia.

Authors:  Uwe Wollina; Dana Langner; Gesina Hansel; Jacqueline Schönlebe
Journal:  Wien Med Wochenschr       Date:  2016-07-05

Review 7.  Interleukin-1 loop model for pathogenesis of Langerhans cell histiocytosis.

Authors:  Ichiro Murakami; Michiko Matsushita; Takeshi Iwasaki; Satoshi Kuwamoto; Masako Kato; Keiko Nagata; Yasushi Horie; Kazuhiko Hayashi; Toshihiko Imamura; Akira Morimoto; Shinsaku Imashuku; Jean Gogusev; Francis Jaubert; Katsuyoshi Takata; Takashi Oka; Tadashi Yoshino
Journal:  Cell Commun Signal       Date:  2015-02-22       Impact factor: 5.712

Review 8.  Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies.

Authors:  Caroline Hutter; Milen Minkov
Journal:  Immunotargets Ther       Date:  2016-10-12

9.  Frequency detection of BRAF V600E mutation in a cohort of pediatric langerhans cell histiocytosis patients by next-generation sequencing.

Authors:  Shunqiao Feng; Lin Han; Mei Yue; Dixiao Zhong; Jing Cao; Yibing Guo; Yanling Sun; Hao Zhang; Zhenhua Cao; Xiaodai Cui; Rong Liu
Journal:  Orphanet J Rare Dis       Date:  2021-06-11       Impact factor: 4.123

10.  Cutaneous Langerhans cell histiocytosis with gastrointestinal involvement treated with dabrafenib.

Authors:  Jacob R Stewart; Era C Murzaku; Titilola T Sode; Katherine A Gordon
Journal:  JAAD Case Rep       Date:  2017-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.